NCT06465628 Acupressure on Xerostomia in Head and Neck Cancer Patients
| NCT ID | NCT06465628 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The University of Hong Kong |
| Condition | Head and Neck Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 126 participants |
| Start Date | 2024-12-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 126 participants in total. It began in 2024-12-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a randomized controlled trial aimed to1) examine the effect of a self-administered acupressure intervention on head and neck cancer patients with xerostomia (primary outcome) relative to oral health education control; 2) examine the effect of self-administered acupressure on secondary outcomes, including quality of life and severity of symptoms of head and neck cancer patients; 3) evaluate patients' expectancy of acupressure; 4) explore the acceptability of self-administered acupressure for head and neck cancer patients with xerostomia. Hypothesis: self-administered acupressure has better effect on xerostomia for head and neck cancer patients comparing to oral health education. Acupressure will also benefit head and neck cancer patients on quality of life and severity of symptoms. Head and neck cancer patients may have good acceptability of self-administered acupressure.
Eligibility Criteria
Inclusion Criteria: * age ≥18 years; * able to give informed consent; * diagnosed with head and neck cancer (cancers in the head and neck region, e.g. oral cancer, nasopharyngeal cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, sinus cancer, salivary gland cancer); * completed radiation therapy or chemoradiotherapy for at least 2 weeks; * complains of xerostomia after the treatment; * able to communicate in Cantonese or Mandarin. Exclusion Criteria: * history of xerostomia prior to head and neck cancer treatment (e.g., Sjögren Syndrome); * practiced acupressure or received acupuncture in the last 3 months; * having contraindications to acupressure, e.g. blood system disease (e.g., leukemia); pregnancy; lactating; upper or lower extremity deformities; infection or injuries at the acupoints. Those who are taking medications/alternative substances to treat xerostomia on a fixed dosage regimen in the past one month will not be excluded. \-
Contact & Investigator
Denise Cheung, PhD
PRINCIPAL INVESTIGATOR
School of Nursing, the University of Hong Kong
Frequently Asked Questions
Who can join the NCT06465628 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Head and Neck Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06465628 currently recruiting?
Yes, NCT06465628 is actively recruiting participants. Contact the research team at denisest@hku.hk for enrollment information.
Where is the NCT06465628 trial being conducted?
This trial is being conducted at Hong Kong, Hong Kong.
Who is sponsoring the NCT06465628 clinical trial?
NCT06465628 is sponsored by The University of Hong Kong. The principal investigator is Denise Cheung, PhD at School of Nursing, the University of Hong Kong. The trial plans to enroll 126 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.